Hints and tips:
Related Special Reports
...AstraZeneca’s chair has hit out at proxy advisers for “double standards” that “do serious harm” to the competitiveness of UK companies, after more than a third of the company’s shareholders voted against...
...Soriot already earns more than bosses of larger European pharmaceutical companies....
...Soriot’s new pay deal comes after the company hit a $45bn sales target in 2023 that the chief executive had set in 2014 when the company fended off a takeover bid from US rival Pfizer....
...The company has struggled with its own supply issues....
...The Biosecure Act would prohibit US companies receiving federal grant money from working with four Chinese biotech companies, including WuXi AppTec and its sister company WuXi Biologics, which produce active...
...The company is also a partner for several pharmaceutical companies....
...This has proved lucrative for the companies....
...These shifts have led some companies to remove the UK from their supply chains....
...This means the German company is the sole supplier of a treatment that has become a standard of care in recent years....
...Following the dividend raise, shares in the company closed 2.3 per cent higher on Thursday....
...Novo Nordisk purchased Dicerna Pharmaceuticals, a company focused in RNA-based therapeutics, for $3.3bn in 2021....
...The company’s immunotherapy drug Imfinzi helped patients with so-called limited stage small cell lung cancer survive for longer....
...by Swiss company Novartis....
...Soaring sales of the products have pushed the companies’ valuations to record highs....
...The company will increase its footprint at a Cambridge biomedical site and build a vaccine manufacturing site in Speke in Liverpool....
...The government wants to unlock £50bn of capital from pension funds to invest in companies such as private equity and early-stage companies by 2030....
...In a statement on Thursday, the UK-based pharmaceutical company said that it would pay a $3.10-per-share dividend for 2024, 20 cents above the 2023 payout, “underlining the company’s confidence in its performance...
...Biotech companies have worked to apply the technology since Doudna and Charpentier’s discovery....
...The deal will give the Danish pharmaceutical company a treatment for heart failure currently in mid-stage, phase 2 trials that targets root causes of heart disease....
...In November, the company entered the race to develop an obesity drug, signing a licensing agreement with Chinese company Eccogene to develop an oral obesity pill, in contrast to Eli Lilly and Novo Nordisk...
...About 1,000 people in England would have been eligible for the treatment, according to estimates by the watchdog and companies....
...The company would present more precise survival data from the Tagrisso trial at a conference later this year, she added....
...According to health data company Airfinity, there are 232 anti-obesity medications at various stages of development, from pre-clinical studies on animals to late-stage, phase 3 trials....
...“Unfortunately, it’s a trend that we’ve seen for a number of companies....
...Demand in the US and Europe is surging for treatments such as Wegovy, the weight-loss drug from Danish company Novo Nordisk, which was shown in a trial to reduce the risk of death by 18 per cent....
International Edition